CD63 and COVID-19: (2021) with a cohort of over 40% severe COVID‐19 patients using capture beads‐based analytics platform, a significant increase of CD63+ EVs was observed in COVID‐19 patients compared to healthy controls where no statistically significant difference was observed in our study.